OBJECTIVE: The present study was performed to examine whether the blood pressure (BP)-lowering effects of soluble epoxide hydrolase (sEH) inhibition in two-kidney, one-clip (2K1C) Goldblatt hypertension are nitric oxide (NO) dependent. METHODS: Mice lacking the endothelial NO synthase (eNOS) gene (eNOS-/-) and their wild-type controls (eNOS+/+) underwent clipping of one renal artery. BP was monitored by radiotelemetry and the treatment with the sEH inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohex-yloxy]-benzoic acid (c-AUCB) was initiated on day 25 after clipping and lasted for 14 days. Renal concentrations of epoxyeicosatrienoic acids (EETs) and their inactive metabolite dihydroxyeicosatrienoic acids (DHETs) were measured in the nonclipped kidney. Renal NO synthase (NOS) activity was determined by measuring the rate of formation of L-[(14)C]citruline from L-[(14)C]arginine. RESULTS: Treatment with the sEH inhibitor elicited similar BP decreases that were associated with increases in daily sodium excretion in 2K1C eNOS+/+ as well as 2K1C eNOS-/- mice. In addition, treatment with the sEH inhibitor increased the ratio of EETs/DHETs in the nonclipped kidney of 2K1C eNOS+/+ as well as 2K1C eNOS-/- mice. Treatment with the sEH inhibitor did not alter renal NOS activity in any of the experimental groups. CONCLUSIONS: Collectively, our present data suggest that the BP-lowering effects of chronic sEH inhibition in 2K1C mice are mainly associated with normalization of the reduced availability of biologically active EETs in the nonclipped kidney and their direct natriuretic actions.
OBJECTIVE: The present study was performed to examine whether the blood pressure (BP)-lowering effects of soluble epoxide hydrolase (sEH) inhibition in two-kidney, one-clip (2K1C) Goldblatt hypertension are nitric oxide (NO) dependent. METHODS:Mice lacking the endothelial NO synthase (eNOS) gene (eNOS-/-) and their wild-type controls (eNOS+/+) underwent clipping of one renal artery. BP was monitored by radiotelemetry and the treatment with the sEH inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohex-yloxy]-benzoic acid (c-AUCB) was initiated on day 25 after clipping and lasted for 14 days. Renal concentrations of epoxyeicosatrienoic acids (EETs) and their inactive metabolite dihydroxyeicosatrienoic acids (DHETs) were measured in the nonclipped kidney. Renal NO synthase (NOS) activity was determined by measuring the rate of formation of L-[(14)C]citruline from L-[(14)C]arginine. RESULTS: Treatment with the sEH inhibitor elicited similar BP decreases that were associated with increases in daily sodium excretion in 2K1C eNOS+/+ as well as 2K1C eNOS-/- mice. In addition, treatment with the sEH inhibitor increased the ratio of EETs/DHETs in the nonclipped kidney of 2K1C eNOS+/+ as well as 2K1C eNOS-/- mice. Treatment with the sEH inhibitor did not alter renal NOS activity in any of the experimental groups. CONCLUSIONS: Collectively, our present data suggest that the BP-lowering effects of chronic sEH inhibition in 2K1C mice are mainly associated with normalization of the reduced availability of biologically active EETs in the nonclipped kidney and their direct natriuretic actions.
Authors: Ludek Cervenka; Ivana Vanecková; Zuzana Husková; Zdenka Vanourková; Michaela Erbanová; Monika Thumová; Petra Skaroupková; Martin Opocenský; Jan Malý; Vera Certíková Chábová; Vladimír Tesar; Marcela Bürgelová; Ondrej Viklický; Vladimír Teplan; Michal Zelízko; Herbert J Kramer; L Gabriel Navar Journal: J Hypertens Date: 2008-07 Impact factor: 4.844
Authors: Marlina Manhiani; Jeffrey E Quigley; Sarah F Knight; Shiva Tasoobshirazi; TarRhonda Moore; Michael W Brands; Bruce D Hammock; John D Imig Journal: Am J Physiol Renal Physiol Date: 2009-06-24
Authors: L Červenka; V Melenovský; Z Husková; A Sporková; M Bürgelová; P Škaroupková; S H Hwang; B D Hammock; J D Imig; J Sadowski Journal: Physiol Res Date: 2015-06-05 Impact factor: 1.881
Authors: I A Bukhari; B I Alorainey; A A Al-Motrefi; A Mahmoud; W B Campbell; B D Hammock Journal: Eur Rev Med Pharmacol Sci Date: 2020-08 Impact factor: 3.507
Authors: Alexandra Sporková; Rami N Reddy; John R Falck; John D Imig; Libor Kopkan; Janusz Sadowski; Luděk Červenka Journal: Am J Med Sci Date: 2016-02-23 Impact factor: 2.378
Authors: Arzu Ulu; Kin Sing Stephen Lee; Christina Miyabe; Jun Yang; Bruce G Hammock; Hua Dong; Bruce D Hammock Journal: J Cardiovasc Pharmacol Date: 2014-07 Impact factor: 3.105
Authors: Alexandra Sporková; Sárka Jíchová; Zuzana Husková; Libor Kopkan; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Herbert J Kramer; Luděk Cervenka Journal: Clin Exp Pharmacol Physiol Date: 2014-12 Impact factor: 2.557
Authors: Petr Kujal; Vera Čertíková Chábová; Petra Škaroupková; Zuzana Husková; Zdena Vernerová; Herbert J Kramer; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Kento Kitada; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Ludek Červenka Journal: Clin Exp Pharmacol Physiol Date: 2014-03 Impact factor: 2.557